Therefore, for early detection and launch of specific treatment of Graves’ disease, screening for thyroid hormone and anti-thyroid stimulating hormone receptor antibody levels is necessary when treating patients with periodic paralysis. The gene discussed is TSHR; the disease is periodic paralysis.